Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum HAVN Life Sciences Inc C.HAVN

Alternate Symbol(s):  HAVLF

HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities... see more

CSE:HAVN - Post Discussion

HAVN Life Sciences Inc > HAVN News Release - GREAT NEWS
View:
Post by Idvhmz123 on Jul 27, 2021 8:45am

HAVN News Release - GREAT NEWS

ORIGINAL: HAVN Life Signs Agreement to Enable Export of Psilocybin into Canada, the US and Europe 2021-07-27 08:01 ET - News Release The Agreement with P.A. Benjamin Manufacturing Company whom operates a GMP compliant facility in Jamaica VANCOUVER, BC / ACCESSWIRE / July 27, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FRA:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announced a new agreement with P.A. Benjamin Manufacturing Company ("PAB"), a pharmaceutical manufacturing company based in Kingston, Jamaica. PAB operates a GMP compliant facility and will be contract packing HAVN Life naturally-derived psilocybin, following the necessary protocols to allow for export from Jamaica and import into Canada, the US and Europe. Along with HAVN Life's collaboration with Hypha Wellness, a Jamaican food and psychoactive mushroom producer, this agreement further reinforces the Company's commitment to collaboration and long-term industry growth in Jamaica. Further building out this psychedelic supply chain puts HAVN Life in an excellent position to be an early mover, as markets begin to open up around the globe. The agreement will also open the door for HAVN Life to seek API designations, as well as secure further supply agreements with companies seeking high-quality and naturally derived psilocybin. "As a new industry it is critical that there is stakeholder partnership and as such the partnership between Jamaican GMP manufacturer, P.A. Benjamins, Hypha Wellness, and HAVN Life Sciences is a step in the right direction" remarks Hon. Floyd Green, MP, Minister of Agriculture and Fisheries. "The sustainability of the industry will depend largely on our ability to effectively research psilocybin mushrooms and to combine Agriculture with manufacturing," he adds. "This partnership with PAB is absolutely key for our ability to supply safe, quality-controlled psilocybin API's to researchers and patients around the globe," says HAVN Life CEO, Tim Moore. "The agreement will make HAVN Life the first company in the Caribbean Community and Common Market with GMP capabilities for psilocybin-a huge step towards our goal to be at the forefront of the international psychedelic supply chain framework," he adds. "We're excited and committed to work with HAVN Life Science and Hypha Wellness to export psilocybin, and build our research and development partnerships," says Christopher Powell, Director at P.A. Benjamin Manufacturing Company. "Working with Jamaican stakeholders and the GMP manufacturer P.A. Benjamin's, we're focused on developing a framework for manufacturing and exports," says Benjamin Graeme, Founder, Director at Hypha Wellness. "It's an exciting time as Jamaica has a unique value position in the international market, and the means to supply it," he adds. The agreement and packaging of psilocybin through PAB's GMP compliant facility will be in compliance with Health Canada and local guidelines.
Comment by bud13 on Jul 27, 2021 2:54pm
lol. Taper. Great news. And down we go. !!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities